Researchers found that PET with the radiotracer F-18 FluorThanatrace was able to provide effective PARP-1 level measurement and visualization in all breast cancer tumors and metastases in women with various breast cancer subtypes, while another study showed that fluciclovine PET was able to monitor tumor glutamine level changes brought by the glutaminase inhibitor CB-839 in women with triple-negative breast cancer. "These studies are important steps toward developing much-needed, non-invasive imaging tests to help measure and predict inhibitor responses and guide treatments for women with a wide range of breast cancers," said Dr. David Mankoff, co-senior author of both studies presented at the San Antonio Breast Cancer Symposium.
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.